Fourth Quarter 2025 Earnings Presentation March 2026 Important notice Cautionary Note Regarding Forward-Looking Statements and Projections. Certain statements in this presentation may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, each as amended. Forward-looking statements provide current expectations of future events and include any statemen ...

4 th Quarter 2025 Earnings Presentation Mar 2026 Disclaimer Agenda 4 th Quarter 2025 Achievements and Growth Strategies Recent Developments 4 th Quarter 2025 Financial Performance Overview 01 02 03 The information in this presentation is provided to you by Yalla Group Limited (the "Company") solely for informational purposes and is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any security or instrument of the Company, or to participate in any investment activity or trading stra ...

Creative Media & Community Trust (NasdaqGM:CMCT) Q4 2025 Earnings call March 09, 2026 05:00 PM ET Company Participants Brandon Hill - CFO and Treasurer David Thompson - CEO Steve Altebrando - Portfolio Oversight Operator Afternoon, welcome to the Creative Media & Community Trust fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there ...

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [22][23] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an expansion of 570 basis points from the prior year [20][21] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli, while the adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [21][24] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8][19] - Women's health is a significant focus, with investments in launching this offering, including the acquisition of Optimal Human Health MD and partnerships with recognized experts in the field [5][6] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and is onboarding approximately 1,200 new patients daily, reflecting strong brand demand [3][19] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15][16] Company Strategy and Development Direction - LifeMD is focused on leveraging artificial intelligence to enhance care delivery, diagnostics, and patient operations, with plans to launch an AI clinical decision support tool in the first half of 2026 [11][12] - The company aims to build a comprehensive virtual healthcare platform that integrates emerging AI capabilities and insurance benefits, enhancing patient experience and operational efficiency [16][17] - LifeMD is committed to expanding its pharmacy operations, which are now licensed in all 50 states, to support personalized compounded medications and improve margins [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [18] - The company anticipates returning to adjusted EBITDA profitability in Q2 2026, with revenue guidance for 2026 projected between $220 million and $230 million [25] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, allowing for aggressive investment in growth initiatives [3][24] - The company is seeing significant pipeline opportunities with large pharmaceutical companies, enhancing its attractiveness as a partner in the healthcare space [5] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [29] Question: Revenue model for Wegovy pill - The Wegovy pill is typically priced at $249 per month, with healthy gross margins around $100 per order [31] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, expecting to drive patient acquisition and revenue growth [34] Question: Drivers of revenue increase in 2026 - Growth will primarily come from subscriber count increases in the GLP-1 weight management business, women's health, and the Rex MD brand [37] Question: Women's health performance compared to other markets - Early performance in women's health shows higher intent and promising retention rates, with significant investments made in marketing and brand development [44][46] Question: Stickiness of Wegovy pill versus injectable - Initial retention rates for the Wegovy pill are better than the injectable, but long-term retention remains to be seen [54] Question: Comparison with competitors like Amazon - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering synchronous care and a range of specialty services [56][58]

Summary of iBio Conference Call Company Overview - **Company**: iBio (NYSEAM:IBIO) - **Industry**: Biotechnology, specifically focusing on cardiometabolic diseases and obesity treatments Key Points and Arguments Long-term Vision - iBio pivoted into the cardiometabolic space two years ago, focusing on treatments that follow GLP-1s, which are becoming a cornerstone in obesity treatment. The company aims to address unmet needs in patient care within this space [7][8] Value Inflection Points - Upcoming milestones include: - External data from Wave and Arrowhead - Filing for Activin E by the end of the year, with potential interim data by the end of next year - Progress on bispecific myostatin activin A program, expected to enter the clinic in the second half of next year - Myostatin program acceptance in Australia, with first patient dosing anticipated in Q3 [12][12][12] IBIO-610 (Activin E Antibody) - The antibody targets the Activin E pathway at the protein level in blood, differentiating it from competitors focusing on gene-level interventions [25] - Aiming for near-complete inhibition of the pathway, which may lead to better efficacy compared to competitors [26] - Safety profile is expected to be favorable due to the extensive history of antibody use [29] - Designed for long-acting subcutaneous administration, with a half-life of approximately 100 days in humans [33] Competitive Landscape - iBio is learning from competitors' data on visceral fat and liver fat reductions, which may inform their trial designs and patient populations [35][36] - The company is particularly interested in inflammation biomarkers, which could link to cardiovascular disease protection [40][41] Regulatory Considerations - The company is cautious about regulatory pathways, emphasizing the need for endpoints that reflect real patient benefits rather than just weight loss [44][45] Patient Populations - Targeting a broad range of patients, including those with type 2 diabetes, liver fibrosis, and obstructive sleep apnea [51][52] - The potential for the drug to address weight maintenance in obesity is highlighted as a significant unmet need [49] Pipeline and Future Indications - iBio is developing a bispecific antibody targeting myostatin, GDF11, and activin A, which may address multi-organ diseases like heart failure with preserved ejection fraction [58][59] - The company is not focused on rare diseases but is open to partnerships for those indications [62] Financial Overview - iBio has cash reserves extending into Q1 2028, prioritizing the development of Activin E, bispecific, and myostatin programs [71] - Current market cap is approximately $350 million, with a fully diluted cap closer to $500 million [71] Partnership Strategy - iBio is considering partnerships for larger indications like obesity, while smaller indications may be developed independently [73] - The company is selective in partnerships, aiming to maximize shareholder value [74] Underappreciated Aspects - The team, platform, and persistence are highlighted as key strengths that differentiate iBio in the competitive landscape [77] Additional Important Content - The integration of AI in drug discovery is emphasized, allowing for the development of more effective and manufacturable antibodies [66][68] - The company is focused on optimizing both antibodies and antigens, which sets it apart from competitors [67][68]

Protagonist Therapeutics Conference Call Summary Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Industry**: Biotechnology, specifically focused on peptide technology for drug development Key Points and Arguments 2026 Outlook - Protagonist Therapeutics is anticipating a significant year in 2026 with two potential FDA approvals for partnered products and ongoing data from its early pipeline [3][4] - The company has a strong financial position, funding new efforts with its own resources and maintaining a surplus cash balance, which will be used to maximize shareholder value [4] Product Pipeline - **IL-23 Receptor Antagonist**: Partnered with Johnson & Johnson (J&J), NDA filed in July 2025, with expected approval in Q3 2026 [4][5] - **Rusfertide (Hepcidin Mimetic)**: Partnered with Takeda, received priority review with NDA filed by the end of 2025, also expected approval in Q3 2026 [5][6] - The partnership with Takeda is structured as a 50-50 co-development and co-commercialization agreement, with an option for Protagonist to opt-in for a $400 million milestone payment [6][28] Market Potential - The oral IL-23 blocker is the first of its kind, with significant market potential as J&J's research indicates that over 75% of patients currently on injectables would switch to an oral option [14][15] - The company believes that the oral formulation could not only capture market share from injectables but also create a new market segment [15] Clinical Data and Efficacy - The company reported a 30% clinical remission rate in ulcerative colitis from phase two studies, indicating strong efficacy [17] - The mechanism of action targets the IL-23 receptor, which is overexpressed in gastrointestinal tissues, potentially leading to better outcomes in inflammatory bowel disease compared to existing treatments [19][20] Future Developments - Protagonist is advancing multiple assets, including oral IL-17 and oral hepcidin candidates, with phase one studies expected to yield important data [7][8][36] - The oral IL-17 candidate (PN-881) aims to achieve high potency and specificity, with a focus on both A and F isoforms, which is critical for efficacy in treating conditions like psoriasis [38][39] Strategic Considerations - The company is considering the balance between opting out of the rusfertide partnership for a substantial upfront payment versus co-promoting the drug, weighing the benefits of financial security against potential long-term gains [28][30] - Protagonist is also exploring the development of a franchise around IL-17 compounds, with a focus on psoriasis and potentially other indications [50][52] Competitive Landscape - The company acknowledges the competitive nature of the obesity and metabolic disease space, with plans to differentiate its oral triple G agonist from existing injectable options [54][55] - Protagonist aims to achieve both significant weight loss and improved safety profiles, positioning its products as versatile options for patients [59][60] Additional Important Insights - The company is committed to maintaining confidentiality around clinical data until strategic decisions are made, with plans to share findings at medical conferences rather than immediately [43] - Protagonist's approach to drug development emphasizes the advantages of peptides over small molecules, particularly in terms of potency and specificity [49] This summary encapsulates the key insights from the Protagonist Therapeutics conference call, highlighting the company's strategic direction, product pipeline, and market potential within the biotechnology sector.

Axsome Therapeutics Conference Call Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Date**: March 09, 2026 - **Key Speakers**: Mark Jacobson (COO), Nick Pizzie (CFO) Key Points Auvelity Performance and Strategy - Auvelity annualized revenue at the end of 2025 was just over **$600 million**, marking its third full year since launch in 2022, outperforming peers in the market [6][7] - The sales force expanded from **160** to **300** representatives in 2025, with plans to double to **600** in 2026, focusing on Major Depressive Disorder (MDD) and the anticipated approval for Agitation in Alzheimer’s Disease (ADA) [7][8] - Peak sales projections for Auvelity are estimated between **$1 billion** to **$3 billion** for MDD and **$1.5 billion** to **$3 billion** for ADA [7] - Market access has improved to **86%** coverage of total lives, with **100%** coverage in the government channel and **78%** on the commercial side [21][22] - Direct-to-consumer (DTC) advertising began in September 2025, with adjustments made based on learnings from the initial campaign [18][19] Clinical and Market Dynamics - Auvelity's clinical profile shows a distinct safety and tolerability profile, with over **50%** of prescriptions now coming from first and second-line treatments [8][9] - The product is gaining traction in primary care, with about **33%** of scripts originating from this sector [9] - The company is reallocating resources from DTC to expand the sales team, anticipating that this will enhance the effectiveness of future DTC campaigns [18][19] Upcoming Indications and Trials - The PDUFA date for ADA is set for **April 30, 2026**, with preparations underway for potential FDA approval [23][24] - Axsome is also exploring a smoking cessation indication for Auvelity, with clinical operations set to begin soon [30][32] Symbravo Launch - Symbravo is performing well in the migraine space, with a focus on later-line treatment due to payer management [36][37] - The sales force for Symbravo is currently **100 reps**, with a strategy to refine the launch based on early utilization data [40][41] - Market access for Symbravo is around **50%** covered lives, with recent contracts signed to improve access [45] Sunosi Growth - Sunosi has seen a **40%** year-over-year growth, supported by a dedicated team of **70 reps** [55][57] - The company is optimistic about further accelerating revenue through four indications currently in development [57] AXS-14 and AXS-17 Developments - AXS-14 (esreboxetine) is targeting the fibromyalgia market, with a new phase 3 trial launched after a previous Refuse to File due to trial design issues [87][89] - AXS-17 is a new product for epilepsy, with plans for phase 2 enabling work in 2026, focusing on unmet needs in the epilepsy space [106][107] AXS-12 Submission - AXS-12, targeting narcolepsy with a focus on cataplexy, is at the NDA stage, with submission expected soon [121] Additional Insights - The company is strategically focusing on expanding its pipeline and market presence while addressing regulatory feedback to enhance product approvals [89][90] - There is a strong emphasis on understanding market dynamics and patient needs to drive product utilization and acceptance [41][57]

Summary of Arvinas Conference Call Company Overview - **Company**: Arvinas (NasdaqGS:ARVN) - **Focus**: Development of PROTAC degraders, with four programs currently in phase one across various disease areas [5][6] Key Programs and Developments - **Pipeline**: - **Vepdegestrant**: Positive pivotal phase trial readout for ER degrader [6] - **Bavdegalutamide**: Outlicensed to Novartis, providing a strong foundation for future growth [6] - **ARV-102**: LRRK2 degrader targeting neurodegeneration, showing promise in reducing LRRK2 levels in cerebrospinal fluid [39][40] - **ARV-806**: KRAS G12D degrader for solid tumors, with rapid enrollment in clinical trials [128] - **ARV-393**: BCL6 degrader in phase 1 studies for B-cell and T-cell lymphomas, showing early responses [142][143] - **ARV-027**: Polyglutamine repeat AR degrader for Kennedy's disease, recently started in clinical trials [145] - **ARV-6723**: HPK1 degrader planned for future clinical use [146] Competitive Advantages - **PROTAC Technology**: - Allows for iterative degradation, overcoming resistance mechanisms that traditional inhibitors face [27][28] - Offers oral bioavailability and the ability to cross the blood-brain barrier, which is advantageous for treating neurodegenerative diseases [28] - **Differentiation**: Each program is focused on demonstrating unique benefits over existing therapies, such as improved efficacy and reduced resistance [20][21] Market Position and Strategy - **Commercialization**: Arvinas is seeking a new partner for the commercialization of vepdegestrant while focusing resources on earlier pipeline assets [18][19] - **Combination Therapies**: Emphasis on developing combination strategies, particularly for oncology applications, to enhance treatment efficacy [139] Clinical Insights - **LRRK2 and Neurodegeneration**: - Targeting LRRK2 is crucial for diseases like Parkinson's and progressive supranuclear palsy, with a goal to reduce LRRK2 levels by 50% to halt disease progression [81][82] - Preclinical data supports the potential for ARV-102 to impact pathologic proteins associated with these diseases [41][42] - **KRAS G12D**: - The ARV-806 program aims to demonstrate superior efficacy compared to existing inhibitors, with a focus on overcoming compensatory upregulation seen in traditional therapies [119][120] Upcoming Milestones - **Data Releases**: Anticipated data from ongoing trials, including results from ARV-102 in Parkinson's disease patients and updates on ARV-806 [68][128] - **Phase 1b Trial**: Plans to initiate a phase 1b trial for progressive supranuclear palsy by mid-year [68] Conclusion - Arvinas is positioned as a leader in the development of PROTAC degraders, with a robust pipeline and strategic focus on differentiation and combination therapies. The company is actively pursuing partnerships and preparing for significant clinical data releases in the near future.

Summary of Adagene Conference Call Company Overview - **Company**: Adagene (NasdaqGM:ADAG) - **Event**: 2026 Conference on March 09, 2026 - **Key Speaker**: Mickael Chane-Du, Chief Strategy Officer Core Points and Arguments Product Differentiation - **Lead Program**: ADG126 (Muzastotug), a next-generation masked conditional CTLA-4 antagonist - **Differentiation Factors**: 1. **Unique Backbone**: ADG126 binds to a different epitope than ipilimumab, resulting in a significantly stronger antibody-drug conjugate (ADC) with a potency believed to be 10x higher than ipilimumab [4][10] 2. **Proprietary Masking Technology**: Utilizes SafeBody, a protease-sensitive peptide, which offers better masking efficiency compared to competitors like Exelixis [4][5] Clinical Data and Efficacy - **MSS CRC (Microsatellite Stable Colorectal Cancer)**: - Standard care yields poor outcomes with response rates in the mid-single digits and median overall survival (OS) in the low teens [13] - ADG126 combined with pembrolizumab shows a confirmed response rate between 15% and 29%, significantly higher than the 2.5% response rate for nivolumab and ipilimumab in similar populations [17][14] - The higher the dose, the better the response rate, with ongoing studies showing a dose-dependent response profile [20][36] Safety and Tolerability - **Adverse Events**: Low incidence of grade 3 treatment-related adverse events (<10%) and no grade 4 or 5 events reported [10] - **Durability of Response**: Emphasis on the importance of durability in treatment outcomes, with ongoing follow-up data expected to provide insights into long-term survival benefits [34][36] Future Updates and Trials - Upcoming data updates expected to provide further insights into the efficacy and safety of ADG126 in combination with pembrolizumab in late-line MSS CRC [22][36] - Plans to present data from a randomized study involving ADG126 in combination with atezolizumab and bevacizumab for hepatocellular carcinoma (HCC) [77][81] Competitive Landscape - Comparison with other treatments, such as the zanzelitinib and atezolizumab combination, which has shown a response rate of around 5-9% [46][49] - ADG126's confirmed response rate at higher doses is close to 30%, indicating a competitive edge [49] Collaborations and Partnerships - Recent collaboration with Sanofi, including a $25 million equity investment and a phase 1/2 trial evaluating ADG126 combined with Sanofi's bispecific PD-1/IL-15 [99][100] - Ongoing collaboration with Exelixis to apply SafeBody technology to various biologics [106] Additional Research and Development - Exploration of ADG126's potential in other tumor types beyond MSS CRC, including earlier lines of therapy and patients with liver metastasis [96][98] - Development of T-cell engagers targeting HER2 and CD20, with a focus on reducing cytokine release syndrome [110][111] Important but Overlooked Content - The emphasis on the balance between efficacy and safety in dosing strategies, particularly in the context of maintaining long-term treatment benefits [41][43] - The potential for ADG126 to be a safer CTLA-4 option that can be combined with various regimens, enhancing its applicability in immuno-oncology [59][60]

Summary of Signet Jewelers (NYSE: SIG) 2026 Conference Call Company Overview - **Company**: Signet Jewelers - **Ticker**: NYSE: SIG - **Conference Date**: March 09, 2026 Key Points Industry Performance - The jewelry industry experienced a strong holiday season, particularly during the peak days leading up to Christmas, which were critical for sales performance [4][3] - There was a sequential improvement in sales month by month during the quarter, despite initial consumer hesitance in November due to external pressures [3][4] Financial Highlights - Preliminary results for Q4 indicate positive comparable sales (comps) during the holiday season, with a strong performance continuing into January [4][5] - The company generated over $500 million in free cash flow, representing a 20% year-over-year increase, with relatively flat inventory levels [7][5] - Operating income was delivered at the high end of guidance, despite some margin decline due to increased promotional activity [5][6] Consumer Behavior Insights - The company operates two distinct businesses: fine jewelry year-round and a gift-giving business during the holiday season [14][16] - Consumers showed a willingness to trade up for higher quality items, particularly in the $200-$1,000 price range, while lower price points faced challenges [16][17] - The promotional environment was more competitive, particularly affecting lower and middle-income consumers [17][5] Brand Performance - Core brands such as Kay, Zales, and Jared returned to positive comps for the first time since fiscal year 2022, with a 3% increase in these businesses [7][6] - Blue Nile showed positive performance, while James Allen continued to be a drag on overall results [36][38] - Zales experienced a pullback in Q4, attributed to a focus on self-purchase rather than gift-giving [39][40] Strategic Priorities - The company plans to focus on brand differentiation and marketing efforts in 2026, with an emphasis on enhancing customer experience [96][97] - There is a strategic review of underperforming brands, with potential for turnaround plans or divestitures [82][83] - The company is not prioritizing M&A but is focused on organic investments, particularly in core brands [119][120] Tariff and Commodity Management - The company has navigated tariff changes effectively, with a focus on supply chain flexibility and resetting supplier agreements [61][62] - Gold and silver prices have increased, and the company is exploring alternative materials to manage costs [69][70] - The impact of tariffs and commodity costs will continue to be monitored, with expectations of some lumpiness in gross margins in the first half of the year [137][138] Future Outlook - The company anticipates a resilient consumer base, despite potential economic pressures, and is preparing for a dynamic environment in 2026 [75][78] - There is a focus on leveraging insights from key selling periods like Valentine's Day to inform strategies for Mother's Day and other peak periods [46][48] - The company aims to maintain a healthy fleet of stores while considering strategic pruning where necessary [122][124] Conclusion - Signet Jewelers is positioned to capitalize on its core brands and consumer trends while navigating external challenges such as tariffs and commodity prices. The focus on brand differentiation and customer experience is expected to drive growth in 2026.